Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

REVERT- Breast Cancer: Phase 1b/2 Study of the Addition of STAT3 Inhibitor TTI-101 to Reverse Resistance to Palbociclib or Ribociclib Plus Aromatase Inhibitor or Fulvestrant Therapy for Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer

NCT05384119 is registered in ClinicalTrials.gov with Tvardi Therapeutics, Incorporated as lead sponsor.

NCT NCT05384119
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05384119 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
REVERT- Breast Cancer: Phase 1b/2 Study of the Addition of STAT3 Inhibitor TTI-101 to Reverse Resistance to Palbociclib or Ribociclib Plus Aromatase Inhibitor or Fulvestrant Therapy for Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer
Lead sponsor
Tvardi Therapeutics, Incorporated
Phase
Phase 1
Overall status
Terminated
Start date
January 9, 2023
Completion date
May 6, 2024
Enrollment
6 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer